For all press and media enquiries please contact mediarelations@chiesi.com
PARMA, Italy - Nov. 12, 2025 – Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to advance blood-brain barrier (BBB)-crossing platform technology in lysosomal storage disorders (LSD) to address challenging…
Exclusive collaboration and license agreement for the development and global commercialization of Arbor’s clinical-stage gene editing program, ABO-101 for primary hyperoxaluria type 1 (PH1) Multitarget research collaboration and option agreement for Arbor’s innovative gene editing technologies for…
Chiesi Group and Serna Bio have entered into a collaboration agreement to discover and develop novel small molecule drugs directed to respiratory diseases. The partnership will leverage Serna’s proprietary RNA-targeting small molecule discovery platform. Serna Bio's innovative technology enables the…
Design of multi-center study is based on previous Phase 2a clinical data, which showed a decrease in the occurrence of severe bronchopulmonary dysplasia (BPD) OHB-607 has the potential to be the first innovative respiratory therapeutic advance for extremely preterm neonates in over thirty years. Oak…
The collaboration is underpinned by a shared commitment to advancing medical science and improving patient care through joint research, development, and innovation efforts Parma, 14 May 2024 – Chiesi Group, a research-oriented international biopharmaceutical group, proudly announces the signing of a…
Strategic collaboration to leverage Chiesi's legacy of respiratory leadership and Gossamer Bio's development expertise in pulmonary hypertension. Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales…
Chiesi Group and Oak Hill Bio will collaborate closely to develop OHB-607, a clinical-stage investigational drug candidate, to treat complications of extremely premature birth; This agreement expands Chiesi’s commitment to Neonatology, a highly strategic area for the company; Partners intend to…
Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases. This agreement expands Chiesi’s comprehensive R&D program in bronchiectasis, a respiratory disease with high unmet medical needs,…
Chiesi Group and Affibody will collaborate closely to develop novel Affibody ® molecules as innovative treatments for respiratory diseases. This agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with high unmet medical needs. Affibody will receive an upfront payment,…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
